Literature DB >> 16361271

Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase.

Gema Santamaría1, Marta Martínez-Diez, Isabel Fabregat, José M Cuezva.   

Abstract

There is a large body of clinical data documenting that most human carcinomas contain reduced levels of the catalytic subunit of the mitochondrial H+-ATP synthase. In colon and lung cancer this alteration correlates with a poor patient prognosis. Furthermore, recent findings in colon cancer cells indicate that downregulation of the H+-ATP synthase is linked to the resistance of the cells to chemotherapy. However, the mechanism by which the H+-ATP synthase participates in cancer progression is unknown. In this work, we show that inhibitors of the H+-ATP synthase delay staurosporine (STS)-induced cell death in liver cells that are dependent on oxidative phosphorylation for energy provision whereas it has no effect on glycolytic cells. Efficient execution of cell death requires the generation of reactive oxygen species (ROS) controlled by the activity of the H+-ATP synthase in a process that is concurrent with the rapid disorganization of the cellular mitochondrial network. The generation of ROS after STS treatment is highly dependent on the mitochondrial membrane potential and most likely caused by reverse electron flow to Complex I. The generated ROS promote the carbonylation and covalent modification of cellular and mitochondrial proteins. Inhibition of the activity of the H+-ATP synthase blunted ROS production prevented the oxidation of cellular proteins and the modification of mitochondrial proteins delaying the release of cytochrome c and the execution of cell death. The results in this work establish the downregulation of the H+-ATP synthase, and thus of oxidative phosphorylation, as part of the molecular strategy adapted by cancer cells to avoid ROS-mediated cell death. Furthermore, the results provide a mechanistic explanation to understand chemotherapeutic resistance of cancer cells that rely on glycolysis as the main energy provision pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16361271     DOI: 10.1093/carcin/bgi315

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  41 in total

1.  Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype.

Authors:  Laura Sánchez-Cenizo; Laura Formentini; Marcos Aldea; Alvaro D Ortega; Paula García-Huerta; María Sánchez-Aragó; José M Cuezva
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

2.  Fully automated software for quantitative measurements of mitochondrial morphology.

Authors:  P Mason McClatchey; Amy C Keller; Ron Bouchard; Leslie A Knaub; Jane E B Reusch
Journal:  Mitochondrion       Date:  2015-12-11       Impact factor: 4.160

Review 3.  Metabolic genes in cancer: their roles in tumor progression and clinical implications.

Authors:  Eiji Furuta; Hiroshi Okuda; Aya Kobayashi; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2010-02-01

4.  ATP5b and β2-microglobulin are predictive markers for the prognosis of patients with gallbladder cancer.

Authors:  Jianning Sun; Zhu-Lin Yang; Xiongying Miao; Qiong Zou; Jinghe Li; Lufeng Liang; Guixiang Zeng; Senlin Chen
Journal:  J Mol Histol       Date:  2014-10-14       Impact factor: 2.611

Review 5.  A message emerging from development: the repression of mitochondrial beta-F1-ATPase expression in cancer.

Authors:  José M Cuezva; María Sánchez-Aragó; Sandra Sala; Amaya Blanco-Rivero; Alvaro D Ortega
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945

6.  In vivo inhibition of the mitochondrial H+-ATP synthase in neurons promotes metabolic preconditioning.

Authors:  Laura Formentini; Marta P Pereira; Laura Sánchez-Cenizo; Fulvio Santacatterina; José J Lucas; Carmen Navarro; Alberto Martínez-Serrano; José M Cuezva
Journal:  EMBO J       Date:  2014-02-12       Impact factor: 11.598

Review 7.  Mitochondria-mediated energy adaption in cancer: the H(+)-ATP synthase-geared switch of metabolism in human tumors.

Authors:  María Sánchez-Aragó; Laura Formentini; José M Cuezva
Journal:  Antioxid Redox Signal       Date:  2012-09-24       Impact factor: 8.401

8.  LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.

Authors:  Han Xie; Vladimir A Valera; Maria J Merino; Angela M Amato; Sabina Signoretti; William M Linehan; Vikas P Sukhatme; Pankaj Seth
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

9.  Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells.

Authors:  Millie A Behera; Qunsheng Dai; Rachana Garde; Carrie Saner; Emily Jungheim; Thomas M Price
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-08-18       Impact factor: 4.310

10.  Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells.

Authors:  Ying-Ying Lu; Tong-Sheng Chen; Jun-Le Qu; Wen-Liang Pan; Lei Sun; Xun-Bin Wei
Journal:  J Biomed Sci       Date:  2009-02-02       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.